75
Participants
Start Date
April 29, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
October 31, 2026
Avexitide
Avexitide (also known as exendin 9-39), a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is a 31-amino acid peptide with a free amino group at the N-terminus and an amidated C-terminus. By binding to the GLP-1 receptor, avexitide inhibits GLP-1 receptor signaling, thereby reducing GLP-1 receptor-mediated insulin secretion
Placebo
Matching placebo comparator
RECRUITING
Penn Medicine University City, Philadelphia
RECRUITING
Georgia Clincal Research, Lawrenceville
RECRUITING
East Coast Institute for Research, Jacksonville
RECRUITING
Southern Endocrinology & Diabetes Associates, Mesquite
RECRUITING
Stanford Health Care - Endocrinology Clinic, Stanford
RECRUITING
University of Colorado Health Anschutz Medical Campus, Aurora
RECRUITING
Hanson Diabetes Center, Port Charlotte
RECRUITING
Cotton-O'Neil Diabetes and Endocrinology Center, Topeka
RECRUITING
Brigham and Women's Hospital, Boston
RECRUITING
Joslin Diabetes Center, Boston
RECRUITING
NYC Health + Hospitals/Queens - BRANY, New Hyde Park
RECRUITING
Duke Center for Metabolic and Weight Loss Surgery, Durham
RECRUITING
Lucas Research - Morehead City, Morehead City
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Vanderbilt Weight Loss Center, Nashville
RECRUITING
Endocrine and Psychiatry Center, Houston
RECRUITING
UT Health San Antonio, San Antonio
RECRUITING
Diabetes and Gandular Disease Clinic, San Antonio
RECRUITING
Consano Clinical Research, Shavano Park
RECRUITING
Texas Valley Clinical Research, LLC, Weslaco
RECRUITING
UWHealth - Junction Rd Medical Center Endocrinology Clinic, Madison
Lead Sponsor
Amylyx Pharmaceuticals Inc.
INDUSTRY